Insurance reimbursement concerns sink Orexigen
September 11, 2014 at 17:27 PM EDT
The Food and Drug
Administration approved Orexigen Therapeutics Inc.'s (Nasdaq: OREX) obesity
treatment Contrave but concerns about health insurance reimbursements
weighed down the stock 62 cents to close at $5.28.
